Modality
Small Molecule
MOA
DLL3 ADC
Target
Tau
Pathway
Hedgehog
LGS
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
~Nov 2018
→ ~Feb 2020
Phase 3
May 2020
→ Aug 2027
Phase 3Current
NCT05675248
2,601 pts·LGS
2023-09→2025-01·Completed
NCT05613550
1,210 pts·LGS
2021-12→2027-04·Not yet recruiting
NCT07069028
830 pts·LGS
2020-05→2026-01·Terminated
+1 more trial
6,589 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-01-191.2y agoPh3 Readout· LGS
2026-01-043mo agoPh3 Readout· LGS
2027-04-211.1y awayPh3 Readout· LGS
2027-08-021.3y awayPh3 Readout· LGS
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P3
Termina…
P3
Not yet…
P3
Complet…
P3
Complet…
Catalysts
Ph3 Readout
2025-01-19 · 1.2y ago
LGS
Ph3 Readout
2026-01-04 · 3mo ago
LGS
Ph3 Readout
2027-04-21 · 1.1y away
LGS
Ph3 Readout
2027-08-02 · 1.3y away
LGS
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05675248 | Phase 3 | LGS | Completed | 2601 | FEV1 |
| NCT05613550 | Phase 3 | LGS | Not yet recr... | 1210 | CR |
| NCT07069028 | Phase 3 | LGS | Terminated | 830 | VA |
| NCT03229436 | Phase 3 | LGS | Completed | 1948 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| TER-5062 | Terns | Phase 2/3 | Tau | |
| GLP-3342 | Galapagos | Phase 1/2 | PLK4 | |
| SOB-2861 | Sobi | Phase 2 | RET |